Jin-Zhen oral liquid for pediatric coronavirus disease (COVID-19): A randomly controlled, open-label, and non-inferiority trial at multiple clinical centers

Background: As the coronavirus disease 2019 (COVID-19) pandemic progressed, especially with the emergence of the Omicron variant, the proportion of infected children and adolescents increased significantly. Some treatment such as Chinese herbal medicine has been administered for COVID-19 as a therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Qian, Qiao, Hongmei, Jiang, Huiyi, Liu, Lixiao, Ge, Yanling, Zong, Fang-Jiao, Li, Yanan, Dong, Bingzi, Hu, Sujuan, Meng, Dongmei, Jin, Rong, Wang, Xiangshi, Chang, Hailing, Xu, Xiaolong, Wang, Chenjing, Cao, Yu, Zhang, Han-Ting, Liu, Qingquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008848/
https://www.ncbi.nlm.nih.gov/pubmed/36923353
http://dx.doi.org/10.3389/fphar.2023.1094089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008848/
https://www.ncbi.nlm.nih.gov/pubmed/36923353
http://dx.doi.org/10.3389/fphar.2023.1094089

Ejemplares similares